Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPASALT dapagliflozin natriuresis mechanistic study
NL-OMON49588Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Average change in 24-hour sodium excretion from baseline to Days 2 to 4. Started Jul 2017; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON49588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49588.